All Industries

Top Biotech Companies

3,960 Biotech companies, sorted by total funding raised.

Pathos

Pathos is an AI-enabled biotechnology company focused on re-engineering drug development.

Chicago, United States51–200Artificial Intelligence, Biotech
Series D·$365.0M·May 2025
Windward Bio

Clinical-stage drug development company improving outcomes for people with advanced immunological...

Basel, United States1–10Biotech, Healthcare
Growth Equity·$365.0M·May 2026
DELFI Diagnostics

Develops blood-based liquid biopsy tests using fragmentomics and machine learning to detect and m...

Baltimore, United States51–200Artificial Intelligence, Biotech
Venture Round·$364.8M·Dec 2025
Oricell Therapeutics

Clinical-stage oncology company developing novel CAR-T cell therapies for hematological malignanc...

Shanghai, China51–200Oncology, Therapeutics
Venture Round·$364.0M·Apr 2026
Umoja

Develops in vivo CAR T cell therapies that generate CAR T cells inside patients to treat cancer.

Seattle, United States201–500Biotech, Drug Discovery
Series C·$363.0M·Jan 2025
Ventus Therapeutics

Clinical-stage biopharmaceutical company using structural biology and computational chemistry to ...

Montreal, Canada11–50Biotech, Drug Discovery
Grant·$360.1M·Apr 2023
Terremoto Biosciences

Clinical-stage biotech company using covalent chemistry to develop small molecule medicines for o...

Biotech
Series C·$358.0M·Jan 2025
BE Biopharma

Biotech company pioneering Engineered B Cell Medicines (BCMs) to treat genetic diseases like Hemo...

Cambridge, United States51–200Biotech, Healthcare
Series C·$356.0M·Jan 2025
Enveda

Biotechnology company using AI to learn from life's chemistry and discover medicines 4X faster.

Boulder, United States201–500Biotech
Series C·$355.0M·Nov 2024
PIONYR ImmunotherapeuticsClosed

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenviron...

South San Francisco, United States51–200Biotech, Healthcare
Corporate Round·$355.0M·Jun 2020
ExscientiaAcquired

AI-driven drug design and development company using machine learning to create more effective med...

Oxford, United Kingdom201–500Artificial Intelligence, Biotech
Series D·$351.0M·Apr 2021
Nephron Pharmaceuticals

Pharmaceutical manufacturing and specialty drug company.

West Columbia, United States501–1000Biotech, Healthcare
Venture Round·$350.0M·Aug 2023
PozenClosed

POZEN Inc. is a pharmaceutical company developing therapeutic advancements for diseases with unme...

Chapel Hill, United StatesBiotech
Corporate Round·$350.0M
AffinivaxAcquired

Vaccine development platform leveraging technology from Boston Children's Hospital.

Cambridge, United States51–200Biotech, Healthcare
Series C·$348.5M·Jan 2021
Hemab Therapeutics

Bi-specific antibodies for hemophilia and rare bleeding disorders

Cambridge11–50Biotech, Healthcare
Series C·$347.0M·Mar 2026
Immatics N.V.IPO

Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...

Tuebingen, Germany201–500Biotech, Healthcare
Corporate Round·$346.7M·Dec 2025
Remilk

Precision fermentation company producing animal-free dairy proteins.

Rehovot, Israel51–200Food Tech, Biotech
Venture Round·$346.3M·May 2026
Dewpoint Therapeutics

Biotech company applying biomolecular condensate science to drug discovery across oncology, neuro...

Boston, United States51–200Life Sciences, Biotech
Series D·$346.1M·Sep 2025
Anteris Technologies Global Corp.IPO

Anteris Technologies is a structural heart company developing the DurAVR biomimetic transcatheter...

Eagan, United States51–200Biotech, Healthcare
Growth Equity·$344.1M·Jan 2025
Capstan TherapeuticsClosed

Biotech developing in vivo CAR-T cell therapies. Acquired by AbbVie for $2.1B upfront in 2024.

San Diego, United States51–200Biotech, Healthcare
Series B·$340.0M·Mar 2024
Aspen Neuroscience

Biotech company developing the first autologous iPSC-derived neuron replacement cell therapy for ...

San Diego, United States51–200Biotech, Healthcare
Series C·$339.0M·Nov 2025
Prime MedicineIPO

Biotechnology company developing one-time curative genetic therapies using Prime Editing, a preci...

Cambridge, United States201–500Biotech, Healthcare
Grant·$339.0M·Jul 2025
AgomAb Therapeutics NVIPO

Clinical-stage biopharmaceutical company developing novel disease-modifying therapies for immunol...

Antwerp, Belgium11–50Biotech, Healthcare
Series D·$337.8M·Jan 2024
A
Angitia

Clinical-stage biotechnology company developing bispecific therapeutics for bone diseases with si...

11–50Biotech, Healthcare
Series D·$336.0M·Feb 2026
GreenLight BioIPO

RNA biotech using a cell-free platform to produce RNA solutions for agriculture, human health, an...

Medford, United States51–200Biotech
Series C·$335.0M·Mar 2025